Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
European Journal of Cancer (Oxford, England : 1990)
|
May 8, 2021
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
Giuseppe Curigliano, Miguel Martin, Komal Jhaveri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
B Besse, R S Heist, V A Papadmitrakopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2011
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
G R Blumenschein, F Kabbinavar, H Menon, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
ESMO Open
|
June 28, 2023
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
J Rodon Ahnert, D S-W Tan, I Garrido-Laguna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)
M Martín, A Chan, L Dirix, et al.
Breast Cancer Research : BCR
|
August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
P Neven, P A Fasching, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J M Weiss, T Csoszi, M Maglakelidze, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
European Journal of Cancer (Oxford, England : 1990)
|
May 8, 2021
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
Giuseppe Curigliano, Miguel Martin, Komal Jhaveri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
B Besse, R S Heist, V A Papadmitrakopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2011
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
G R Blumenschein, F Kabbinavar, H Menon, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
ESMO Open
|
June 28, 2023
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
J Rodon Ahnert, D S-W Tan, I Garrido-Laguna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)
M Martín, A Chan, L Dirix, et al.
Breast Cancer Research : BCR
|
August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
P Neven, P A Fasching, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J M Weiss, T Csoszi, M Maglakelidze, et al.
Page
of 2